Discussion stirs around BioAmber Inc. (NYSE:BIOA) this week; here is what analysts are saying.

February 7, 2018 - By Louis Casey

 Discussion stirs around BioAmber Inc. (NYSE:BIOA) this week; here is what analysts are saying.
Investors sentiment decreased to 0.61 in Q3 2017. Its down 0.48, from 1.09 in 2017Q2. It worsened, as 11 investors sold BioAmber Inc. shares while 7 reduced holdings. 4 funds opened positions while 7 raised stakes. 7.40 million shares or 55.46% less from 16.61 million shares in 2017Q2 were reported.
Lpl Fincl Limited Liability invested in 46,000 shares or 0% of the stock. Virtu Ltd Com invested in 0% or 10,090 shares. Morgan Stanley invested in 0% or 120,697 shares. Fmr Ltd Liability Corp has invested 0% in BioAmber Inc. (NYSE:BIOA). 161,049 are owned by Vanguard. Moreover, Blackrock has 0% invested in BioAmber Inc. (NYSE:BIOA) for 130,841 shares. Brown Advisory Inc holds 0% of its portfolio in BioAmber Inc. (NYSE:BIOA) for 23,249 shares. Bridgeway owns 201,700 shares or 0% of their US portfolio. Northern Tru Corporation reported 46,169 shares. Bankshares Of Montreal Can owns 2,000 shares. 142,608 were reported by Levin Cap Strategies Ltd Partnership. Two Sigma Securities Ltd Llc holds 0% or 30,218 shares. Raymond James Advsrs Incorporated accumulated 31,527 shares. Deutsche National Bank Ag invested in 638,517 shares. Mawer invested in 10,000 shares.

BioAmber Inc. (NYSE:BIOA) Ratings Coverage

Among 3 analysts covering Bioamber (NYSE:BIOA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Bioamber has $18.0 highest and $2.5000 lowest target. $12.13’s average target is 6871.26% above currents $0.174 stock price. Bioamber had 5 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, August 6. The stock of BioAmber Inc. (NYSE:BIOA) earned “Buy” rating by Rodman & Renshaw on Tuesday, January 5. Cowen & Co maintained BioAmber Inc. (NYSE:BIOA) on Monday, July 17 with “Hold” rating. Below is a list of BioAmber Inc. (NYSE:BIOA) latest ratings and price target changes.

08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $12.0

The stock decreased 8.42% or $0.016 during the last trading session, reaching $0.174. About 5.84M shares traded or 460.75% up from the average. BioAmber Inc. (NYSE:BIOA) has declined 32.24% since February 7, 2017 and is downtrending. It has underperformed by 48.94% the S&P500.

BioAmber Inc., an industrial biotechnology company, produces and sells bio-succinic acid to various chemical market clients primarily in the United States and Canada. The company has market cap of $9.07 million. The Company’s proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into chemicals that are replacements for petroleum-derived chemicals. It currently has negative earnings. The companyÂ’s bio-succinic acid is used in various applications, including plasticizers, polyurethanes, personal care products, resins and coatings, de-icing solutions, PET resins, lubricants, polybutylene succinate, fine chemicals, and food additives.

More news for BioAmber Inc. (NYSE:BIOA) were recently published by: Streetinsider.com, which released: “BioAmber (BIOA) Canadian Subsidiary Restructures Credit Facility” on January 26, 2018. Prnewswire.com‘s article titled: “BioAmber Inc. Announces Pricing of US$10 Million Underwritten Public Offering” and published on February 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.